Whilst the COVID-19 pandemic caused a step change in global investment for infectious diseases, there remains significant unmet need for broad-spectrum antivirals that can address infection and prevent serious illness.

ILC Therapeutics CEO Owain Millington authored a piece in Drug Discovery World about the need for innovative, broad-spectrum therapies that display pleiotropy, and how ILC’s hybrid interferon platform may be uniquely positioned to tackle these issues. 

Read the full issue here: https://www.ddw-online.com/ddw-winter-2024-2025-33097-202501/